Participants in the San Antonio Breast Cancer Symposium today heard evidence that exemestane may be an effective alternative to anastrozole in adjuvant aromatase inhibitor therapy for early breast cancer, in a study titled: Final Analysis of NCIC CTG MA.27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Hormone Receptor Positive Primary Breast Cancer.

For more information from SABCS 2010, please click here: SABCS 2010.

Produced by The Doctor’s Channel